Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-ketamine and serum metabolism after cytoreductive surgery for ovarian cancer
ChiCTR2200055515Phase 4Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of esketamine in ovarian cancer (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Serum proteomics. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR2200055515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055515.